These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 25313010

  • 21. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
    Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E.
    Curr Drug Targets; 2014; 15(14):1331-40. PubMed ID: 25483224
    [Abstract] [Full Text] [Related]

  • 22. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q, Wang Y, Wang R, Lai W, Tang L, Tao Y, Liu Y, Zhang R, Huang L, Xiang H, Zeng S, Gou L, Chen H, Yao Y, Yang J.
    Eur J Med Chem; 2018 Aug 05; 156():162-179. PubMed ID: 30006162
    [Abstract] [Full Text] [Related]

  • 23. The cytotoxic natural compound erianin binds to colchicine site of β-tubulin and overcomes taxane resistance.
    Yan W, Zhou Y, Yuan X, Bai P, Tang M, Chen L, Wei H, Yang J.
    Bioorg Chem; 2024 Sep 05; 150():107569. PubMed ID: 38905886
    [Abstract] [Full Text] [Related]

  • 24. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
    Yang J, Yan W, Yu Y, Wang Y, Yang T, Xue L, Yuan X, Long C, Liu Z, Chen X, Hu M, Zheng L, Qiu Q, Pei H, Li D, Wang F, Bai P, Wen J, Ye H, Chen L.
    J Biol Chem; 2018 Jun 15; 293(24):9461-9472. PubMed ID: 29691282
    [Abstract] [Full Text] [Related]

  • 25. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity.
    Zheng YB, Gong JH, Liu XJ, Wu SY, Li Y, Xu XD, Shang BY, Zhou JM, Zhu ZL, Si SY, Zhen YS.
    Sci Rep; 2016 Aug 11; 6():31472. PubMed ID: 27510727
    [Abstract] [Full Text] [Related]

  • 26. Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin.
    Sharma A, Sáez-Calvo G, Olieric N, de Asís Balaguer F, Barasoain I, Lamberth C, Díaz JF, Steinmetz MO.
    Int J Mol Sci; 2017 Jun 22; 18(7):. PubMed ID: 28640209
    [Abstract] [Full Text] [Related]

  • 27. Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?
    Michieli P, Di Nicolantonio F.
    Nat Rev Clin Oncol; 2013 Jul 22; 10(7):372-4. PubMed ID: 23712183
    [No Abstract] [Full Text] [Related]

  • 28. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
    Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA.
    Mol Oncol; 2015 Jan 22; 9(1):260-9. PubMed ID: 25226813
    [Abstract] [Full Text] [Related]

  • 29. Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity.
    Li W, Xu F, Shuai W, Sun H, Yao H, Ma C, Xu S, Yao H, Zhu Z, Yang DH, Chen ZS, Xu J.
    J Med Chem; 2019 Jan 24; 62(2):993-1013. PubMed ID: 30525584
    [Abstract] [Full Text] [Related]

  • 30. The novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivo.
    Mu Y, Liu Y, Li L, Tian C, Zhou H, Zhang Q, Yan B.
    PLoS One; 2015 Jan 24; 10(3):e0121806. PubMed ID: 25811876
    [Abstract] [Full Text] [Related]

  • 31. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
    Dinić J, Ríos-Luci C, Karpaviciene I, Cikotiene I, Fernandes MX, Pešić M, Padrón JM.
    Invest New Drugs; 2020 Jun 24; 38(3):584-598. PubMed ID: 31177401
    [Abstract] [Full Text] [Related]

  • 32. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.
    Previdi S, Abbadessa G, Dalò F, France DS, Broggini M.
    Mol Cancer Ther; 2012 Jan 24; 11(1):214-23. PubMed ID: 22027690
    [Abstract] [Full Text] [Related]

  • 33. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
    Podolski-Renić A, Banković J, Dinić J, Ríos-Luci C, Fernandes MX, Ortega N, Kovačević-Grujičić N, Martín VS, Padrón JM, Pešić M.
    Eur J Pharm Sci; 2017 Jul 15; 105():159-168. PubMed ID: 28502672
    [Abstract] [Full Text] [Related]

  • 34. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.
    Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC.
    Mol Cancer Ther; 2017 Jan 15; 16(1):3-15. PubMed ID: 27760837
    [Abstract] [Full Text] [Related]

  • 35. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
    Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM.
    Mol Cancer Ther; 2004 Oct 15; 3(10):1319-27. PubMed ID: 15486199
    [Abstract] [Full Text] [Related]

  • 36. IMB5476, a novel microtubule inhibitor, induces mitotic catastrophe and overcomes multidrug resistance in tumors.
    Zheng YB, Dong YQ, Si SY, Zhen YS, Gong JH.
    Eur J Pharmacol; 2022 Mar 15; 919():174802. PubMed ID: 35143830
    [Abstract] [Full Text] [Related]

  • 37. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC.
    Clin Cancer Res; 2005 Aug 15; 11(16):6002-11. PubMed ID: 16115945
    [Abstract] [Full Text] [Related]

  • 38. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.
    Cancer Res; 2004 Jul 01; 64(13):4621-8. PubMed ID: 15231674
    [Abstract] [Full Text] [Related]

  • 39. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
    Xi WH, Yang LY, Cao ZY, Qian Y.
    Biochem Biophys Res Commun; 2015 Feb 20; 457(4):723-9. PubMed ID: 25623532
    [Abstract] [Full Text] [Related]

  • 40. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
    Zhu C, Zuo Y, Wang R, Liang B, Yue X, Wen G, Shang N, Huang L, Chen Y, Du J, Bu X.
    J Med Chem; 2014 Aug 14; 57(15):6364-82. PubMed ID: 25061803
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.